Trial Profile

A Multicentre, Randomised, Open-label, Phase 2 trial of mifamurtide combined with post-operative chemotherapy for newly diagnosed high risk osteosarcoma patients (metastatic osteosarcoma at diagnosis or localised disease with poor histological response)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mifamurtide (Primary) ; Cisplatin; Doxorubicin; Etoposide; Ifosfamide; Methotrexate
Indications Osteosarcoma
Focus Therapeutic Use
Acronyms SARCOME13

26 Dec 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Jan 2026.
25 Nov 2025 Planned primary completion date changed from 1 Sep 2025 to 1 Dec 2025.
05 Jun 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Sep 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com